12:00 AM
Apr 06, 2009
 |  BC Week In Review  |  Company News  |  Other News

Ziopharm cancer news

Ziopharm refocused and reduced headcount by 4 (19%) to 17, with the cuts in preclinical and clinical development. The company plans to focus on IV palifosfamide ( ZIO-201). The IV formulation of the bi-functional alkylator is...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >